Contents

1 Basic Concepts of Vaccine Immunology 1
1.1 Vaccination and Preventing Infectious Diseases 1
1.2 Microorganisms: Bacteria, Yeasts, Protozoa and Viruses 2
1.3 The Immune System 3
1.3.1 Basics 3
1.3.2 Microbial Clearance 4
1.3.3 Active and Passive Protection from Infectious Diseases 5
1.3.4 Antigenic Variation 5
1.3.5 Tumour Immunology 6
1.4 Prevention of Infectious Diseases by Vaccination 6
1.4.1 Viral and Bacterial Vaccines Currently in Use 8
1.4.2 Routes of Administration 10
1.4.3 Malaria Vaccines 11
1.4.4 Experimental Prophylactic and Therapeutic Vaccines 11

2 Humoral and Cellular Immunity 13
2.1 Humoral Immunity 13
2.1.1 Antibody Titres and Antibody Concentrations 14
2.1.2 Two Assays for Humoral Immunity 14
2.2 Cellular Immunity 15
2.2.1 Assays for Cellular Immunity 16

3 Standard Statistical Methods for the Analysis of Immunogenicity Data 19
3.1 Introduction 19
3.2 Geometric Mean Titres and Concentrations 20
3.2.1 Single Vaccine Group 22
3.2.2 Two Vaccine Groups 23
3.3 Geometric Mean Fold Increase 24
3.3.1 Analysis of a Single Geometric Mean Fold Increase 25
3.3.2 Analysis of Two Geometric Mean Fold Increases 25
3.3.3 A Misconception about Fold Increases and Baseline Imbalance 27

Bibliografische Informationen
http://d-nb.info/1004071078

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

3.4 Two Seroresponse Rates 28
3.4.1 Seroprotection Rate 28
3.4.2 Seroconversion Rate 28
3.5 Analysis of Proportions 29
3.5.1 Analysis of a Single Proportion 29
3.5.2 Comparing Two Proportions 33
3.5.3 The Suissa and Shuster Exact Test for Comparing Two Proportions 36
3.6 Multiple Co-Primary Endpoints and the Intersection–Union Test 39
3.7 The Reverse Cumulative Distribution Plot 39
3.8 Discussion 41
3.9 Sample Size Estimation 42
3.9.1 Comparing Two Geometric Mean Responses 42
3.9.2 Comparing Two Proportions 43
3.9.3 Sample Size Estimation for Trials with Multiple Co-Primary Endpoints 44

4 Antibody Titres and Two Types of Bias 47
4.1 Standard Antibody Titres versus Mid-Value Titres 47
4.2 Censored Antibody Titres and Maximum Likelihood Estimation 49
4.2.1 ML Estimation for Censored Normal Data 50
4.2.2 ML Estimation for Censored Antibody Titres 52

5 Adjusting for Imbalance in Pre-Vaccination State 57
5.1 Imbalance in Pre-Vaccination State 57
5.2 Adjusting for Baseline Imbalance 58
5.3 Analysis of Covariance for Antibody Values 59
5.3.1 A Solution to the Problem of Heteroscedasticity 60
5.3.2 Fitting the Variance Model for Heteroscedasticity 60
5.3.3 ANCOVA for Comparative Clinical Vaccine Trials 62

6 Vaccine Equivalence and Noninferiority Immunogenicity Trials 67
6.1 Equivalence and Noninferiority 67
6.2 Equivalence and Noninferiority Testing 68
6.2.1 Basic Concepts 68
6.2.2 Equivalence and Noninferiority Testing for Normal Data 69
6.2.3 The Confidence Interval Approach to Equivalence and Noninferiority Testing 70
6.3 Equivalence and Noninferiority Vaccine Trials with a Geometric Mean Response as Outcome 70
6.4 Equivalence and Noninferiority Trails with a Seroresponse Rate as Outcome 73
6.5 Vaccine Lot Consistency Trials 74
6.5.1 Lot Consistency and the Confidence Interval Method 74

6.5.2 The Wiens and Iglewicz Test to Inspect the Consistency of Three Vaccine Lots 75
6.6 Discussion 78
6.7 Sample Size Estimation 79
6.7.1 Comparing Two Geometric Mean Responses 79
6.7.2 Comparing Two Seroresponse Rates 82
6.7.3 Lot Consistency Trials 82

7 Vaccine Field Efficacy Trials 85
7.1 Introduction 85
7.2 Some Critical Aspects of Vaccine Field Trials 86
7.2.1 Efficacy versus Effectiveness 86
7.2.2 The Influence of the Sensitivity and Specificity of the Diagnostic Test on the Vaccine Efficacy Estimate 87
7.2.3 Surveillance Period 90
7.3 Incidence Measures for Infection 90
7.3.1 Attack Rate 90
7.3.2 Infection Rate 91
7.3.3 Force of Infection 92
7.4 Statistical Analysis of Vaccine Efficacy Data 93
7.4.1 Comparing Two Attack Rates 94
7.4.2 Comparing Two Infection Rates 95
7.4.3 Comparing Two Force of Infection Functions 97
7.5 Recurrent Infections 99
7.5.1 Average Number of Episodes Experienced by a Subject 99
7.6 Sample Size Estimation 103
7.6.1 Trials Comparing Two Attack Rates 103
7.6.2 Trials Comparing Two Infection Rates 105
7.6.3 Trials Comparing Two Forces of Infection 106

8 Correlates of Protection 107
8.1 Introduction 107
8.2 The Protection Curve 108
8.3 Estimating the Protection Curve 108
8.3.1 Estimating the Protection Curve from Challenge Study Data 108
8.3.2 Estimating a Protection Curve from Vaccine Field Efficacy Study Data 111
8.3.3 Predicting Vaccine Efficacy 113
8.4 Threshold of Protection 113
8.5 Discussion 115

9 Safety of Vaccines 117
9.1 Ensuring Vaccine Safety 117
9.2 Vaccine Safety Surveillance 118
9.3 Safety Data and the Problem of Multiplicity 120
9.4 Vaccine Reactogenicity 124
9.4.1 Local and Systemic Reactions 124
9.4.2 Statistical Analysis of Local and Systemic Reactions 125

A SAS and Floating Point Format for Calculated Variables 131

B Closed-Form Solutions for the Constrained ML Estimators $\tilde{R}_0$ 133

C Simulation Results on Jewell's Correction for the Rate Ratio 135

D Proof of Inequality (3.16) 137

E A Generalized Worst-Case Sensitivity Analysis for a Single Seroresponse Rate for Which the Confidence Interval Must Fall Above a Pre-Specified Bound 139
E.1 Introduction 139
E.2 Motivating Example 140
E.3 Complete-Case and Worst-Case Maximum Likelihood Analyses 140
E.4 Maximum Likelihood Analysis with Missing Data 142
E.5 Generalized Sensitivity Analysis 142
E.6 Concluding Remarks 143
E.7 Technical Notes 144

References 145

Index 149